Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from 60 Degrees Pharmaceuticals, Inc. ( (SXTP) ) is now available.
On January 8, 2026, 60 Degrees Pharmaceuticals made available an investor presentation tied to a RedChip-hosted webinar, providing updated information on its clinical development timelines and regulatory strategy. The materials highlighted growing commercial use of ARAKODA for chronic babesiosis since 2019, improving gross margins despite recent inventory and supply issues, and the company’s efforts to increase malaria-related sales through a targeted commercial pilot that tackles low brand recognition, generic competition, and access barriers. The presentation also underscored management’s view that future ARAKODA sales for chronic babesiosis could ultimately exceed those for malaria and potentially grow by orders of magnitude if regulatory milestones are achieved, positioning the company for significant long-term revenue expansion from a very small current market capitalization base, while reminding investors of going-concern risks, clinical and regulatory uncertainties, and dependence on third-party manufacturing.
The most recent analyst rating on (SXTP) stock is a Sell with a $0.48 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.
Spark’s Take on SXTP Stock
According to Spark, TipRanks’ AI Analyst, SXTP is a Underperform.
The score is pressured primarily by weak financial performance (persistent unprofitability and negative operating/free cash flow) and a pronounced bearish technical setup (price well below key moving averages with negative MACD). Valuation is also constrained by a negative P/E tied to ongoing losses.
To see Spark’s full report on SXTP stock, click here.
More about 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. is a biopharmaceutical company focused on infectious diseases, particularly malaria prevention and the treatment of chronic babesiosis, with its key product ARAKODA (tafenoquine) commercially available in the U.S. The company targets travelers at risk of malaria and patients with babesiosis, and is pursuing expanded indications and regulatory approvals that could significantly increase its addressable market.
Average Trading Volume: 188,694
Technical Sentiment Signal: Sell
Current Market Cap: $2.18M
See more data about SXTP stock on TipRanks’ Stock Analysis page.